

Nevada Cannabis Compliance Board

Meeting Minutes November 20, 2025

The Nevada Cannabis Compliance Board (CCB) held a public meeting at 9:00 a.m. on November 20, 2025 at 700 East Warm Springs Road, Room 150, Las Vegas, Nevada and at the Nevada Department of Taxation 9850 Double R Blvd., Suite 101, Reno, Nevada.

Cannabis Compliance Board Members Present:

Adriana Guzmán Fralick, Chair

Riana Durrett, Vice Chair

Jerrie Merritt

Dr. Vicki Mazzorana

Ondra Berry

Chair Adriana Guzmán Fralick called the meeting to order. Executive Director James Humm took roll.

Chair Guzmán Fralick, Vice Chair Durrett, Members Mazzorana and Berry were present in Las Vegas, and Member Merritt was present via Zoom.

Chair Adriana Guzmán Fralick provided a reminder that online public comment is no longer accepted, however in person comments can be provided in the north and south.

She announced this is her final meeting as Chair of the Cannabis Compliance Board and she is campaigning for office of Nevada Attorney General. Chair Guzmán Fralick said the decision was not an easy one, because becoming chair of the CCB was a dream realized. She expressed appreciation to Governor Lombardo for appointing her to the position and said it was an honor and privilege to serve in the role. Additionally, she expressed gratitude to current CCB Executive Director James Humm and prior Executive Director Tyler Klimas for their leadership, and to the agency chiefs and staff and Deputy Attorneys General for their guidance and counsel, remarking that the agency sets the standard for responsible cannabis regulation.

Chair Guzmán Fralick commented that she has deep respect for the work done by the cannabis industry owners, operators, attorneys, compliance teams, advocates and employees. Finally, she thanked all board members, past and present, and said she cherishes friendships developed and looks toward the future.

Chair Guzmán Fralick opened Agenda Item I.

I. Public Comment

Tara Baker provided an update on her cannabis waste disposal business, Eco Weed Disposal Solutions, stating that it is available to assist with cannabis waste management.

II. Consent Agenda

A. Consideration of Approval of the October 16, 2025, Cannabis Compliance Board Meeting Minutes

B. Consideration of Approval to Extend Final Inspection Deadline to December 01, 2026

1. Inyo Fine Cannabis Dispensary LLC (CLA006)
2. NevadaPURE LLC (CLA007)
3. Serenity Wellness Center LLC (CLA012)
4. TGIG LLC (CLA009)
5. Congeriem 1 LLC (RD266)
6. Congeriem 2 LLC (RD593)
7. Congeriem 4 LLC (RD597)
8. Congeriem 5 LLC (RD602)
9. Eureka New Gen Farms LLC (C186, P122, RD290)
10. Green Cross Nevada LLC (P019)
11. Green Leaf Farms Holdings LLC (C162, P105)
12. Green Therapeutics LLC (RD273)
13. V6E Holdings Inc (C034)

Chair Guzmán Fralick asked for a motion.

Member Berry moved to approve the Consent Agenda, Items A and B.

Member Mazzorana seconded the motion. All Members said aye. Motion carried.

III. Consideration of Proposed Settlement Agreement to Resolve Disciplinary Action

A. Blossum Group LLC Case No. 2025-006 (C059)

Senior Deputy Attorney General Anthony Garasi presented a summary of the proposed settlement agreement with Blossom Group LLC, Case number 2025-006.

Mr. Garasi advised the board that the settlement agreement follows CCB's 2024 audit of facility C059, noting that evidence presented included repeat violations. He reminded the board there is a history of compliance concerns, a prior complaint and letters of concern previously issued.

The current settlement addresses allegations including, but not limited to, failure to properly tag cannabis, failure to properly dispose of cannabis waste, failing to comply with seed-to-sale tracking requirements, failing to timely submit required quarterly reports. Mr. Garasi provided a summary of the response to the complaint, and agreement to resolution.

Chair Guzmán Fralick thanked Mr. Garasi and asked the board for a motion.

Member Berry moved to approve the settlement agreement presented under item III A, for Blossom Group LLC, case number 2025-006.

Member Merritt seconded the motion. All Members said aye. Motion carried.

IV. Consideration of Proposed Security Interests Between Licensees and Financial Institutions

Rachel Branner, Chief Compliance / Audit Investigator, presented an overview of the proposed security interest between Vireo Growth and East West Bank, Western Alliance Bank and Vireo Growth Inc and Chicago Atlantic Credit Advisors.

A. Notice of Proposed Security Interest between Vireo Growth Inc (C062, C070, C094, CLA005, CLA016, D107, D152, D165, D200, P063, P088, RD216, RD217, RD218, RD221, RD397, RD398, RD399, RD401, T024, T056, T095) and East West Bank, Western Alliance Bank, and Vireo Growth Inc and Chicago Atlantic Credit Advisers, LLC

Chief Branner said Vireo Growth is a publicly traded company and parent company to Deep Roots Harvest and Deep Roots Aria Acqco. Ms. Branner advised the board that the Deep Roots licenses will be considered collateral against the repayment terms of the loan, pursuant to the agreement. Should Vireo default, the parties are aware that a transfer of interest will need to be submitted prior to foreclosing on the licenses. She said no areas of concern will prevent CCB from recommending approval of the security interest. Ms. Branner introduced Lori Rogich, Brian Pick, John Mazzarakis, Maggie McLetchie, Gustav Stickley and Charles Corbisiero to the board.

Chair Guzmán Fralick welcomed the attendees.

Lori Rogich, on behalf of Vireo, spoke on behalf of Vireo Growth Inc, Deep Roots Harvest Inc, Deep Roots Aria Acqco Inc and Chicago Atlantic Admin LLC. She introduced attendees on Zoom: John Mazzarakis, co-executive chairman and CEO of Vireo Growth; Peter Sack, managing partner of Chicago Atlantic; Keith Capurro, president and CEO of the Deep Roots entities; and Brian Pick, chief legal officer of Deep Roots entities.

Maggie McLetchie, on behalf of East West Bank, introduced Gus Stickley, lead counsel for East West Bank and said Mr. Stickley is the agent for the lenders on the loan. Additionally, she introduced Charles Corbisiero, managing director from East West Bank.

Ms. Rogich provided a statement stating they seek approval of a security interest as set forth in the loan and security agreements. She explained it is a traditional debt financing arrangement, there is no plan to convert the debt to equity and no mechanism to do so. Ms. Rogich summarized proposed remedies in the event of foreclosure and acknowledged the requirement of a transfer of interest request, and said all documentation demonstrates good faith and regulatory cooperation.

Chair Guzmán Fralick thanked Ms. Rogich and asked the board for questions or a motion.

Member Merritt disclosed that she is an employee of Western Alliance Bank. She discussed this with counsel and it was determined she is not required to abstain.

Member Mazzorana moved to approve Agenda Item IVA, **Notice of Proposed Security Interest between Vireo Growth Inc** (C062, C070, C094, CLA005, CLA016, D107, D152, D165, D200, P063, P088, RD216, RD217, RD218, RD221, RD397, RD398, RD399, RD401, T024, T056, T095) **and East West Bank, Western Alliance Bank, and Vireo Growth Inc and Chicago Atlantic Credit Advisers, LLC**
Member Berry seconded the motion. All Members said aye. Motion carried.

Ms. Rogich thanked CCB Agent Angela Dean for her collaboration, professionalism and patience. She expressed appreciation to Chair Guzmán Fralick for her years of service and guiding hand in the industry and wished her the best. Ms. McLetchie agreed with the comments.

V. **Request for Withdrawal of Transfer of Interest**

A. **Consideration to Approve Withdrawal Request of TOI #21072 for Green Therapeutics LLC (C083,P055, RD273, T036) and Australis Capital Inc**

Rachel Branner, Chief Compliance / Audit Investigator, presented a request to withdraw a transfer of interest between Green Therapeutics and Australis Capital.

Ms. Branner advised the board that after the Canadian Stock Exchange delisted Australis Capital and the purchase price was to be remitted in shares, there was no way for the parties to move forward with the transaction. Green Therapeutics requested withdrawal of the transfer of interest. Ms. Branner introduced Duke Fu and Terry Booth.

Chair Guzmán Fralick welcomed Mr. Fu and asked for a presentation or discussion.

Mr. Fu, representing Green Therapeutics, restated the request to withdraw the transfer due to Australis Capital being delisted and no longer in business. Mr. Fu stated that Green Therapeutics continues to operate with no change.

Chair Guzmán Fralick asked the board for questions or motion.

Member Berry moved to approve the withdrawal of TOI#21072 under item V A.
Member Mazzorana seconded the motion. All Members said aye. Motion carried.

VI. **Request for Transfer of Interest**

Rachel Branner, Chief Compliance / Audit Investigator, presented two transfers of interest.

A. True Harmony Company, LLC (C219, P152) (TOI #2500024 & #2500025) completing an internal transfer of interest and transferring a portion of interest to Michaeline DeJoria Heydari
Chief Branner stated TOI numbers **2500024 and 2500025** request approval for True Harmony Company to complete an internal transfer of 50% ownership from current sole owner John DeJoria to his sister, Michaeline DeJoria Heydari for no consideration. Ms. Heydari will be involved at a high level, but there will be no change in day-to-day operations. No areas of concern were identified to prevent the proposed transfer of interest. Ms. Branner introduced John DeJoria, Michaeline DeJoria Heydari and Robert Kurilko and Catherine Linamen to the board.

Chair Guzmán Fralick welcomed John DeJoria and Robert Kurilko and Michaeline DeJoria Heydari attending via Zoom.

Mr. Kurilko said the request is a non-cash transfer of interest between siblings for their estate planning. Mr. DeJoria currently owns 100% and will give 50% to his elder sister upon the board's approval.

Michaeline DeJoria Heydari confirmed it is for estate planning purposes only, in the event anything occurs.

Chair Guzmán Fralick asked the board for questions or motion.

Member Mazzorana moved to approve Agenda Item VI A, **True Harmony Company, LLC (C219, P152) (TOI #2500024 & #2500025)** internal transfer of interest between two siblings.

Member Berry seconded the motion. All Members said aye. Motion carried.

B. Greenway Health Community L.L.C. (P097) (TOI #2500026) transferring its ownership in P097 to MMJ Investment Facility LLC

Chief Branner stated TOI 2500026 requests for approval for Greenway Health Community LLC to transfer 100% of its ownership in its production license to MMJ Investment Facility LLC. Ms. Branner advised the board that MMJ Investment Facility is a privately held Nevada company, solely owned by Michael Viellion who is the existing owner of GBS Nevada Partners, dba ShowGrow. MMJ requested a waiver of NCCR 5.110 pursuant to 5.112. CCB staff suggests limiting the waiver to expire on the next TOI agenda date. Ms. Branner noted no areas of concern were developed during the investigation and introduced Alicia Ashcraft, Michael Viellion and Daniel Caravette as available to answer any questions.

Ms. Ashcraft greeted the board and thanked CCB Investigators Dana Lauren and Maggie Adams for their work. She said that Mr. Viellion is new to the cannabis industry and the acquisition of this production facility will strengthen their presence in the industry.

Mr. Viellion addressed the board and said he and Mr. Caravette have done business for a while, and enjoy a good relationship with the board, and they wish to continue to keep everyone employed and maintain business as usual.

Chair Guzmán Fralick asked about a stipulation and order from January 2025 which included a two-year probationary period.

Ms. Ashcraft confirmed that the stipulations under settlement for disciplinary action would fall off if a 100% transfer of interest occurred and that the assessed fine was paid in full. She advised that Mr. Viellion is aware of the details of the settlement agreement, and all matters are resolved.

Chair Guzmán Fralick asked for a motion.

Member Durrett moved to approve Agenda Item VI B, **Greenway Health Community L.L.C. (P097) (TOI #2500026)** transferring its ownership in P097 to MMJ Investment Facility LLC

with a waiver of NCCR 5.110 pursuant to 5.112 for any future transfers of less than five percent, subject to the condition the waiver expires on the next agenda date.

Member Merritt seconded the motion. All Members said aye. Motion carried.

VII. **Petition filed Pursuant to NRS 678B.633**

A. Terance Jackson (for possible action)

Chair Guzmán Fralick **tabled** this item.

Chair Guzmán Fralick announced that she will move to postpone consideration of LCB File sections 61, 63, 65, 66, and 71—all of which incorporate ASTM standards—until the January 26, 2026, board meeting.

On the November 2025 agenda, these sections appear under **Item VIII.I (Regulation 11)** as follows:

- Section 61 → Item 1
- Section 63 → Item 3
- Section 65 → Item 5
- Section 66 → Item 6
- Section 71 → Item 11

She explained that the regulations currently listed under Item VIII are outdated. The board is now considering whether to adopt updated 2024 regulations that were previously submitted to the Legislative Counsel Bureau (LCB) and returned to the board for approval. Additional changes were made during the 2025 legislative session. As a result, the board must first review the outdated regulations, decide which ones (if any) to approve, and make necessary adjustments to the remaining provisions.

VIII. Consideration of Proposed Adoption, Amendment, and/or Repeal of the Nevada Cannabis Compliance Regulations (LCB File No. R152-24) (for possible action) (public comment)

Deputy Director Michael Miles introduced Agenda Item VIII, noting an opportunity for public comment will be provided. He clarified the presented regulations are not outdated; they were approved from the 2023 legislative session and following solicitation of input from the industry in January 2024. The regulations were workshopped in March, April and May 2024 under APA requirements, and included small business impact statements.

Mr. Miles announced that the CCB held a workshop on SB157 on November 19, 2025, and public workshops are scheduled on December 2 and December 4, 2025, for the legislative session. He opened Item VIII for public comment and apologized for the short notice on the workshop and reminded everyone this is the first time it was done under the APA process, noting the Legislative Council Bureau (LCB) made updates to the regulations to follow legal requirements.

A. Regulation 1. Issuance of Regulations; Construction; Definitions

1. NCCR 1.XXX “Day” defined.
2. NCCR 1.083 “Diversion” defined.
3. NCCR 1.XXX “Edible cannabis product” defined.
3. NCCR 1.113 “Intentionally” defined.
4. NCCR 1.114 “Knowingly” defined.
5. NCCR 1.040 “Definitions”
6. NCCR 1.052 “Advertise” and “advertising” defined.
7. NCCR 1.120 “Letter of approval” defined.
8. NCCR 1.125 “Lot” defined.
9. NCCR 1.130 “Multiple-serving edible cannabis product” defined.
11. NCCR 1.220 “Single-serving edible cannabis product” defined.
12. NCCR 1.222 “Single-use cannabis product” defined.

B. Regulation 4. Disciplinary and Other Proceedings Before The Board

1. NCCR 4.XXX Category I Violations.
2. NCCR 4.XXX Category VII Violations.
3. NCCR 4.XXX Consent or Settlement Agreements.
4. NCCR 4.XXX Petitions submitted to the Board.
5. NCCR 4.XXX Notice of Violation and order to cease activity.
6. NCCR 4.XXX Unlicensed Activity.
7. NCCR 4.XXX Summons or Subpoena for unlicensed activity.
8. NCCR 4.XXX Board actions for unlicensed activity.
9. NCCR 4.XXX Administrative fines.
10. NCCR 4.010 Applicability Chapter change to Chapters 678A and 233B. Repealed.

11. NCCR 4.020 Grounds for disciplinary action.
12. NCCR 4.030 Imposition of civil penalty; revocation or suspension of license or cannabis establishment agent registration card; corrective action.
13. NCCR 4.035 Category II Violations.
14. NCCR 4.040 Category III Violations.
15. NCCR 4.050 Category IV Violations.
16. NCCR 4.055 Category V Violations.
17. NCCR 4.060 Category VI Violations.
18. NCCR 4.065 Imminent health hazard.
19. NCCR 4.070 Complaint.
20. NCCR 4.090 Appearance through counsel.
21. NCCR 4.095 Early case conference and hearing.
22. NCCR 4.100 Reinstatement of license or cannabis establishment agent registration card: Application; conditions, limitations, or restrictions upon reinstatement; denial.
23. NCCR 4.105 Grounds for summary suspension; notice; request for hearing.
24. NCCR 4.110 Discovery: mandatory exchanges.
25. NCCR 4.130 Subpoenas.
26. NCCR 4.135 Disposition of charges: Adjudication by Board. Repealed.
27. NCCR 4.140 Declaratory orders and advisory opinions.
28. NCCR 4.145 Adoption, amendment, or repeal of a regulation.

C. Regulation 5. Licensing, Background Checks, and Registration Cards

1. NCCR 5.000 Application process.
2. NCCR 5.070 Inspections.
3. NCCR 5.075 Authority of Board and Executive Director relating to inspections and investigations, summoning of witnesses and issuance of subpoenas, administration of oaths and administration of provisions of chapter.
4. NCCR 5.090 Notification to Board if cannabis establishment is closing; immediate surrender of license upon permanent closure.
5. NCCR 5.140 Registration Cards: Requirements for requesting replacement card
6. NCCR 5.145 Registration cards: Requirements for changing name or address.

D. Regulation 6. Production and Distribution of Cannabis

1. NCCR 6.010 Establishment of maximum allowable quantity of cannabis products a person may possess for purposes of exemption from state or local prosecution.
2. NCCR 6.025 Board authorized to collect fee for costs for [oversight] investigation; hourly rate.
3. NCCR 6.060 Operation in accordance with plans and specifications included in application; deviation from plans and specifications; documentation of change to facilities; inspection or audit of change to facilities.
4. NCCR 6.080 Inventory control system; authorized sources for acquisition of cannabis and cannabis products; duties of establishment if loss incurred; maintenance and availability of documentation.
5. NCCR 6.082 Use of seed-to-sale tracking system; payment of fees.
6. NCCR 6.085 Required security measures, equipment and personnel; location of outdoor cultivation facility must allow for response by local law enforcement.
7. NCCR 6.120 Restrictions on advertising; required posting of signs in cannabis sales facility.

E. Regulation 7. Cannabis Sales Facility

1. NCCR 7.025 Prohibition on sale that exceeds maximum usable quantity of cannabis.
2. NCCR 7.030 Production required to be offered for sale; restrictions on sale of other products; restrictions on advertising.
3. NCCR 7.035 Storage and location of products; disclosure of cannabis testing facility performing quality assurance tests upon request of consumer; approved sources of products for sale; maintenance and availability of certificate of analysis; exemption for industrial hemp.

4. NCCR 7.050 Delivery to consumer: Restrictions' duties of cannabis establishment agent making delivery.

F. Regulation 8. Cannabis Cultivation Facility

1. NCCR 8.010 Required written disclosure with each lot of usable cannabis; provision of free samples to cannabis sales facility; applicability of provisions governing excise tax on cannabis to free samples.

G. Regulation 9. Production of Cannabis Products

1. NCCR 9.015 Qualifications and duties of persons responsible for managing facility.
2. NCCR 9.045 Edible cannabis products: Testing to ensure homogeneity of potency; requirements for sale; approval of Board required for certain changes.

H. Regulation 10. Minimum Good Manufacturing Practices for Cultivation and Preparation of Cannabis and Cannabis Products or Administration to Humans

1. NCCR 10.075 Cannabis establishment: Establishment of and adherence to written procedures for sanitation; requirement to retain person who is certified applicator of pesticides.

I. Regulation 11. Cannabis Independent Testing Laboratory

1. NCCR 11.XXX New Section references adopted by the Board.
2. NCCR 11.010 Employment, qualifications and duties of scientific director; inspection of testing laboratory upon appointment of new director.
3. NCCR 11.015 Requirements for testing laboratory to handle, test or analyze cannabis.
4. NCCR 11.020 Agreement to become accredited within 1 year after licensure; provision of annual inspection report to Board; inspection by accrediting organization is not substitute for inspection by Board.
5. NCCR 11.025 Adherence to general laboratory standards, practices, procedures and programs; inspection by Board or authorized third party; adoption of publications by reference.
6. NCCR 11.030 Establishment of policies for adequate chain of custody and requirements for samples of products provided to testing laboratory.
7. NCCR 11.045 Limited testing for research and development purposes.
8. NCCR 11.050 Required quality assurance tests; submission of wet cannabis for testing.
9. NCCR 11.060 Performance of testing to verify homogeneity of potency of edible cannabis products.
10. NCCR 11.065 Use of approved pesticides by cannabis establishment; performance of pesticide residue analysis by testing laboratory.
11. NCCR 11.070 Testing: Selection of representative samples and random samples; segregation period for entire lot; duties of testing laboratory; disposal of lot if sample fails test; release of lot if sample passes test; filing of electronic copy of certificate of analysis for tests performed by testing laboratory; grounds for disciplinary action for failure to comply.
12. NCCR 11.075 Testing: Authorized use of cannabis upon failure of microbial screening; automatic failure to pass; request for retest; retest for pesticide residue must be performed by State Department of Agriculture; effect of passing or failing retest.
13. NCCR 11.085 Random quality assurance compliance checks; costs for screening or testing

J. Regulation 12. Packaging and Labeling of Cannabis

1. NCCR 12.XXX Reducing or eradicating microbial contamination disclosure
2. NCCR 12.010 Requirements for singles packages.
3. NCCR 12.015 Requirements for packaging cannabis, cannabis products and edible cannabis products
4. NCCR 12.020 Stamp or mold required for edible cannabis products; exception.
5. NCCR 12.030 Cannabis cultivation facility: Required labeling before sale of cannabis to another cannabis establishment.

6. NCCR 12.035 Cannabis production facility: Required labeling before sale of cannabis products to another cannabis establishment.
7. NCCR 12.040 Cannabis sales facility and cannabis consumption lounge: Required labeling of usable cannabis and single-use cannabis product.
8. NCCR 12.045 Cannabis sales facility and cannabis consumption lounge: Required labeling of cannabis products.
9. NCCR 12.050 Cannabis sales facility and cannabis consumption lounge: Required disclosure and warning.
10. NCCR 12.065 Cannabis treated with radiation. Repealed.
11. NCCR 12.070 Advertising of cannabis.

K. Regulation 13. Cannabis Distributors

1. NCCR 13.010 Requirements for wholesale transportation of cannabis and cannabis products.

L. Regulation 15. Cannabis Consumption Lounge

1. NCCR 15.035 Storage and location of products; disclosure of cannabis independent testing laboratory performing quality assurance tests upon request of consumer; approved sources of products for sale; maintenance and availability of certificate of analysis.
2. NCCR 15.040 On-site requirements to operate a cannabis consumption lounge.

Layke Martin, on behalf of Nevada Cannabis Association submitted written public comment for CCB review and discussed **Sec. 68. NCCR 11.050 (3)** which increases lot size from 10 to 20 grams for all sample sizes, stated doubling the current sample size but not increasing the lot size is contrary to legislative intent. She noted the proportional approach was central to Senate Bill 157 and this change directly contradicts the intent.

Additionally, Ms. Martin commented on the labeling change requirement in **Sec. 81. NCCR 12.045 (1)(f)**, stating that it requires listing the top three terpenes, but most of the products on shelves do not contain the information and there is no clear time frame to work through existing inventory. Ms. Martin suggested an effective date for a delay of 12 months or guidance would be helpful.

Amanda Connor, of Connor and Connor, asked what the next steps are and when they will go into effect if the board votes to approve the regulations today. Mr. Miles responded that there is no time frame; regulations that are approved today will go back to the LCB, the attorneys will review and make sure any minor changes made by CCB are okay, then it returns to the Legislative Commission, with an unknown effective date. Ms. Connor commented on specific regulations below and expressed appreciation to the board for working with the industry regarding imminent health hazard notifications. She requested a different method from the record system, Accella, because there are struggles with that system.

Amanda Connor commented regarding **Sec. 68. NCCR 11.050 (3)** and the 20-gram sample and said arguments exist that the section should not be adopted due to the passage of SB 157 and a discussion to adopt sample sizes proportionate to the increase in lot size. Additionally, she expressed her belief that by adopting a 20-gram sample, the lot size would be eligible to increase without further discussion. Continuing, Ms. Connor spoke on **Sec. 54 NCCR 7.030(5)(b)**, specifically that there was a clarification in prior regulations that said third parties advertising delivery applied only to advertising, not the delivery service platforms which were removed. Ms. Connor commented that the intent is not to require approval for the licenses used by software companies to process deliveries, but the deletion could raise questions. She clarified that the purpose of the language was to state that the software used within the dispensary to process deliveries did not require pre-approval.

Kimberly Maxon-Rushton commented on behalf of RSR Analytical Laboratories. Ms. Maxon-Rushton thanked Chair Guzmán Fralick for holding **Sections 61, 63, 65, 66 and 71**. She expressed concern regarding language returned by LCB that is different from what was submitted and workshopped and said **Sec. 61 NCCR 11** is problematic because LCB returned it with a litany of secondary publications and

standards that laboratories were required to review. Continuing, Ms. Maxon-Rushton said this additional resource requirement is a voluminous and costly endeavor, and it is unclear to which provisions they must adhere. She requested further discussion and/or a workshop and said the industry would be willing to discuss requirements with staff, and it will lead to better regulatory oversight and compliance.

Ms. Maxon-Rushton expressed concern regarding **Sec. 72 NCCR 11.075**, reminding the board that in 2024 the lab specifically requested authority to not have to turn over certificates of analysis (COA) to cultivators until they were paid. This regulation requires a COA to be completed within two days of the completion of all panel tests, submitted to the CCB and the cultivator or producer. She is unable to discern from the proposed regulations whether the standard is in place, noting one section says labs should turn over the COAs to the CCB, and another says the COAs will be posted online. Ms. Maxon-Rushton asked for **Sec. 72** to be completely revised and asked that the board not approve it.

Ms. Maxon-Rushton noted that **Sec. 73 NCCR 11.085** is contrary to legislation passed in 2023, specifically Senate Bill 195 which stated that CCB could not charge fees for certain acts specific to applications. She said the acts are not applications and requested the board not approve **Sec 73** and the amendment to point to 11.085, because it is contrary to statutory intent behind Senate Bill 195.

In conclusion, Ms. Maxon-Rushton addressed a provision in **Sec. 61** which asks labs to adhere to a regulator's guidelines, and said it is not applicable to a licensee. Because of this, she requested withdrawal or tabling of the matter.

Member Mazzorana asked to clarify if the request is to table **Sec. 72 NCCR 11.075 and Sec. 73 NCCR 11.085**. Ms. Maxon-Rushton responded in the affirmative.

Logan Wilson of Jennings & Fulton, spoke on behalf of 374 Labs, G3 Labs, M&A Associates, ERP, NV Cann Labs, RSR Analytical Laboratories, DPL Nevada LLC. Mr. Wilson reminded the board that he assisted Mr. Fulton in the preparation of an executive summary and brief that were submitted in advance of this meeting and urged the board to review the documentation. He said that his clients have addressed statutory, compliance and scientific issues and constitutional arguments and believes that what LCB returned was not what was intended. Mr. Wilson agreed to the postponement of **Sections 61, 63, 65, 66 and 71** and said his clients would like everything to be postponed and workshoped.

Deputy Director Miles addressed the concerns that were raised and said CCB no longer has control over the regulations after the 2023 legislative session, reminding that LCB will make changes according to the legal way the regulations must be listed.

Mr. Miles acknowledged that **Sec. 61** is an issue and CCB will review it in its entirety, although this was a list of standards the CCB will adopt and use in other areas of CCB regulations. He explained that **Sec. 61** is not meant to be an adoption of all standards, requiring industry to follow each one of them, because many of the standards are conflicting. He stated that CCB will continue to clarify this and said all these standards already exist throughout all the regulations but were put into one single list.

Mr. Miles said laboratories are allowed to withhold the certificates of analysis for payment, and there is a rule which requires COAs to be available to the public online, after the laboratories are paid. He asked Kara Cronkhite, Chief of Health and Safety, to respond to comments on **Sec. 72** and **Sec. 73**

Chief Cronkhite addressed **Sec. 73 11.085(3)** and clarified that if CCB directs a laboratory to test product as part of an investigation, the Cannabis establishment responsible for the investigation is required to pay the laboratory for the cost of tests incurred at the CCB's request. It does not bring back any time and effort fees or investigation fees.

Chief Cronkhite said concerns regarding sample collection of 20 grams is not in relation to SB 157; it is language that was workshopped multiple times. CCB believes and science supports that 10 grams is not enough of a representative sample for a five-pound lots of flower or fifteen-pound lots of trim. The board approved the increase to 20 grams as the minimum for five-pound lots of flower or fifteen-pound lots of trim. Any numbers changed for lot sizes must be workshopped, approved by the board and sent to LCB and determined if they are in alignment with SB 157.

Kimberly Maxon-Rushton asked Chief Cronkhite about language under **Sec. 72 NCCR 11.075**, which precludes laboratories from retesting, rerunning and is shown in a different color, reading, “a cannabis independent testing laboratory may not retest a lot, production run or test sample of cannabis or cannabis products or implement internal retesting procedures without the appropriate board approval.” She expressed concern and a request for reconsideration because of instances where a lab must rerun a sample prior to destruction. She requested removal of the language because it is inconsistent with scientific standards.

Deputy Director Miles responded to Ms. Maxon-Rushton and said the issue is not with the number of times retesting is performed after a COA is submitted.

Chief Cronkhite advised that a laboratory can submit a request for research and development after the COA is completed, and CCB could issue a blanket approval which would eliminate the need to submit individual requests.

Deputy Director Miles reminded the public to attend the workshops scheduled for December 2 and December 4 which will provide an opportunity to review and recommend changes to all the regulations.

Amanda Connor asked for clarification on the proposed regulation which will allow a lab to withhold a COA for non-payment. Chief Cronkhite responded that a process is currently in place that allows the COA to be put on hold through METRC while still complying with the two-day notice requirement. The change attempts to provide an option where the COAs are not necessary if the lab has not been paid for the work.

Layke Martin commented on **Sec. 68 NCCR 11.050(3)** stating it creates confusion for licensees regarding doubling the sample size while workshops to increase the sample are occurring. Chair Guzmán Fralick replied that it is very important for agencies to have internal regulations and the ability to fine-tune them, but it is difficult to do while following APA guidelines.

Amanda Connor expressed additional confusion on behalf of her clients regarding sample sizes.

Chief Cronkhite reminded everyone that the changes discussed today are not intended to be workshopped again; they were already workshopped and approved, and the board is simply approving changes made by LCB.

Deputy Director Miles said it was agreed to in 2024 to increase sample sizes to 20 grams and additional changes would result in a lengthy delay.

Chair Guzmán Fralick asked for additional public comments; there were none.

Chair Guzmán Fralick called a recess.

Chair Guzmán Fralick resumed the meeting and moved to postpone all of **Agenda Item I. Regulation 11. Cannabis Independent Testing Laboratory** until a future date due to concerns expressed during public comment, specifically in Sections 61, 63, 65, 66, 68, 71 and 72. Member Berry and Member Mazzorana seconded.

Chair Guzmán Fralick asked for discussion.

Amanda Connor stated her belief that if all of Item I is held, Agenda A, Regulation 1 (8), then NCCR 1.125 “Lot” defined, should be held because it is related to SB157. Deputy Director Miles clarified for the record that there is no change to “Lot” or lot size and should not have been on the agenda. It will not be changed.

Senior Deputy Attorney General Anthony Garasi clarified that “Lot” definition is not being considered.

Chief Cronkhite said there are many changes that are very good and that will benefit the industry, and it would be ideal to get those through without additional review and substantive change. Discussion occurred between the board and Mr. Garasi occurred to clarify options for possible approval or additional changes.

Executive Director James Humm summarized the concern and acknowledged there are issues in NCCR 11 that required additional review with industry, as well as sections that are not disputed. Mr. Humm suggested that postponing all NCCR 11 will result in a cascading effect on approved regulations.

Layke Martin, of Nevada Cannabis Association expressed support for holding all NCCR 11 until a future date.

Chief Cronkhite asked if it is possible to postpone the approval of changes to NCCR 11 and hear it during the January 2026 board meeting for specific sections and send it to LCB for final adoption after final revisions are approved. Mr. Garasi said if a 60-day delay is voted on and approved, it is necessary to re-notice and solicit public comment again.

Senior Deputy Attorney General Allison Herr said the key question is whether the proposed changes to the regulations are **substantive** (i.e., they alter the meaning, requirements, or effect of the rules).

- **If the changes are NOT substantive** (only minor wording, formatting, or non-material clarifications): → No LCB approval is required. The changes can move forward immediately.
- **If the changes ARE substantive** (they modify the actual substance/requirements of the regulations): → LCB approval is required before proceeding.

Available options at this stage:

1. **Postpone action for up to 60 days**
 - Reconsider at the next meeting and then either approve or reject.
 - If rejected after the postponement, the proposal would be sent back to the workshop process for further revision.
2. **Act today**
 - Approve the changes as presented, or
 - Reject them (which would send the proposal back to the workshop process).

In short: Decide today whether to approve, reject, or postpone for up to 60 days (with approval or rejection to follow later).

Chief Cronkhite reminded the board that the vote is on LCB’s technical changes made to the 2024 version which was approved.

Deputy Director Miles suggested removing the list in **Sec. 61** because it caused confusion.

Chair Guzmán Fralick amended her initial motion and moved to **postpone** Agenda Item I Regulation 11. Cannabis Independent Testing Laboratory, Sections 61 through 73 for 60 days (two meetings).

Member Mazzorana asked to clarify that the 60 days means until the January 2026 meeting. Chair Guzmán Fralick confirmed.

Member Berry seconded the motion. All Members said aye. Motion carried.

Chair Guzmán Fralick opened discussion on Agenda Item VIII, Items A, B, C, D, E, F, G, H, J, K, L, omitting Item I, Regulation 11 which was voted on separately.
There was no public comment.

Chair Guzmán Fralick asked for a motion.
Member Berry moved to accept Agenda Item VIII A through L, apart from Item I.
Member Mazzorana seconded the motion. All Members said aye. Motion carried.

IX. Briefing from the Chair and Executive Director

Chair Guzmán Fralick thanked everyone and said she will miss the Cannabis Compliance Board.

Executive Director Humm thanked the board members and staff for executing the regulatory workshops. He expressed appreciation to the industry for engaging in open, transparent dialogue and asked for everyone to attend the workshops scheduled for December 2 and December 4, 2025. Mr. Humm announced Rachel Branner as new Division Chief – Investigations and Enforcement.

Mr. Humm addressed Chair Guzmán Fralick, expressed appreciation for her hard work and for overcoming challenges with the CCB, noting her work with the board was remarkable, her leadership established a firm foundation going forward and he wished her the very best.

Chair Guzmán Fralick continued to Agenda Item X.

X. Next Meeting Date

The next Board meeting date is scheduled for December 18, 2025.

XI. Items for Future Agendas

Chair Guzmán Fralick noted that board members could submit items for future agendas.
Member Berry requested a status check included on the agenda to provide detail where the CCB is on the process, and said it was a highlight working with and serving with Chair Guzmán Fralick.

XII. Public Comment

Member Durrett said farewell to Chair Guzmán Fralick, and that Chair Guzmán Fralick and Executive Director Humm created nice culture and collaboration.

There was no additional public comment.

XIII. Adjournment

Meeting adjourned at 11:03 a.m.